Aggrecanase and Aggrecan degradation in osteoarthritis: A review

Journal of International Medical Research

Volumn 36, Issue 6, 2008, Pages 1149-1160

  Huang, K ^a   Wu, Li Dong ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

ADAMTS; Aggrecan; Aggrecanase; Aggrecanase inhibitors; Osteoarthritis

Indexed keywords

ADAMTS 5 INHIBITOR; AGGRECAN; AGGRECANASE; AGGRECANASE INHIBITOR; METALLOPROTEINASE; METALLOPROTEINASE INHIBITOR; OMEGA 3 FATTY ACID; PROTEIN ADAMTS 4; PROTEIN ADAMTS 5; UNCLASSIFIED DRUG; ACAN PROTEIN, HUMAN; ADAM PROTEIN; ADAMTS5 PROTEIN, HUMAN; AGGRECANASE 1; AGGRECANASE-1; PROCOLLAGEN N PROTEINASE; TIMP3 PROTEIN, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ARTICULAR CARTILAGE; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME STRUCTURE; ENZYME SUBSTRATE; HUMAN; NONHUMAN; OSTEOARTHRITIS; PATHOGENESIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; REVIEW; DRUG ANTAGONISM; ENZYMOLOGY; EXTRACELLULAR MATRIX; METABOLISM;

ADAM PROTEINS; AGGRECANS; EXTRACELLULAR MATRIX; HUMANS; OSTEOARTHRITIS; PROCOLLAGEN N-ENDOPEPTIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 59649094578     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000803600601     Document Type: Review

References (83)

1. Pincus T, Koch GG, Sokka T, et al: A randomised, double-blind, crossover clinical trial of diclofenac plus misoprostol versus acetaminophen in patients with osteoarthritis of the hip or knee. Arthritis Rheum 2001; 44: 1587-1598.
2. Ravaud P, Moulinier L, Giraudeau B, et al: Effects of joint lavage abd steroid injection in patients with osteoarthritis of the knee: results of a multicenter, randomised, controlled trial. Arthritis Rheum 1999; 42: 475-482.
3. Caterson B, Flannery CR, Hughes CE, et al: Mechanism involved in cartilage proteoglycan catabolism. Matrix Biol 2000; 19: 333-344.
4. Sandy JD: Proteolytic Cleavage of Normal and Osteoarthritis Cartilage and Matrix. Oxford: Oxford University Press, 2003; pp. 82-92.
5. Sandy JD: A contentious issue finds some clarity: in the independent and complementary roles of aggrecanase activity and MMP activity in human joint aggrecanalysis. Osteoarthritis Cartilage 2006; 14: 95-100.
6. Tottorella MD, Malfalt AM, Deccico C, et al: The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001; 9: 539-552.
7. Arner EC: Aggrecanase-mediated cartilage degradation. Curr Opin Pharmacol 2002; 2: 322-329.
8. Bondeson J, Wainwright S, Hughes C. et al: The regulation of the ADAMTS4 and ADAMTS5 aggrecanases in osteoarthritis: a review. Clin Exp Rheumatol 2008; 26: 139-145.
9. Tortorella MD, Burn TC, Pratta MC, et al: Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999; 284: 1664-1666.
10. Abbaszade I, Liu RQ, Yang F, et al: Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem 1999; 274: 23443-23450.
11. Hughes CE, Caterson B, Fosang AJ, et al: Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase clevage of aggrecan: application to catabolism in situ and in vitro. Biochem J 1995; 305: 799-804.
12. Ilic MZ, Robinson HC, Handley CJ: Characterization of aggrecan retained and lost from the extracellular matrix of articular catilage. Involvement of carboxyl-terminal processing ic the catbolism of aggrecan. J Biol Chem 1998; 273: 17451-17458.
13. Loulakis P, Shrikhande A, Davis G, et al: N-terminal sequence of proteoglycan fragments isolated from medium of interleukin-1-treated articular-cartilage cultures. Putative site(s) of enzymic cleavage. Biochem J 1992; 284: 589-593.
14. 374) is a primary event in proteolysis of the integlobular domain. J Biol Chem 1995; 270: 2550-2556.
15. Flannery CR, Lark MW, Sandy JD: Identification of a stromelysin cleavage site within the integlobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage. J Biol Chem 1992; 267: 1008-1014.
16. Hu LT, Eskildsen MA, Masgala C, et al: Host metalloproteinases in Lyme arthritis. Arthritis Rheum 2001; 44: 1401-1410.
17. 342) in the aggrecan integlobular domain. J Biol Chem 2002; 277: 16059-16066.
18. Gendron C. Kashiwagi M, Lim NH, et al: Proteolytic activities of human ADAMTS-5: comparative studies with ADAMTS-4. J Biol Chem 2007; 282: 18294-18306.
19. Lohmander LS, Neame PJ, Sandy JD: The structure of aggrecan fragments in human synovial fluid: ecidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint-injury, and osteoarthritis. Arthritis Rheum 1993; 36: 1214-122.
20. 374 bond of the interglobular domain. J Clin Invest 1992; 89: 1512-1516.
21. Arner EC, Pratta MA, Trzaskos JM, et al: Generation and characterization of aggrecanase. A soluble, cartilage-derived aggrecan-degrading activity. J Biol Chem 1999; 274: 6594-6601.
22. Tortorella MD, Pratta M, Liu RQ, et al: Site of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4). J Biol Chem 2000; 275: 18566-18573.
23. Tortorella MD, Liu RQ, Burn T, et al: Characterization of human aggrecanase 2 (ADAM-TS5): substrate specifically studies and comparison with a aggrecanase 1 (ADAM-TS4). Matrix Biol 2002; 21: 499-511.
24. Sandy JD, Verscharen C: Analysis of aggrecan in human, knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss: of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo. Biochem J 2001; 358: 615-626.
25. Sandy JD, Thompson V, Doege K, et al: The intemediates of aggrecanases-dependent cleavage of aggrecan in rat chondrosarcoma cells treated with interleukin-1. Biochem J 2000; 351: 161-166.
26. Tortorella MD, Pratta M, Liu RQ, et al: The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage. J Biol Chem 2000; 275: 25791-25797.
27. Pratta MA, Tortorella MD, Arner EC: Age-related changes in aggrecan glycosylation affect cleavage by aggrecanase. J Biol Chem 2000; 275: 39096-39102.
28. Karsdal MA, Sumer EU, Wulf H, et al: Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. Arthritis Rheum 2007; 56: 1549-1558.
29. Shao X, Hunter CJ: Developing an alginate/chitosan hybrid fiber scaffold for annulus fibrosus cells. J Biomed Mater Res A 2007; 82: 701-710.
30. Llamazares M, Obaya AJ, Moncada-Pazos A, et al: The ADAMTS12 metalloproteinase exhibits anti-tumorigenic prperties through modulation of the Ras-dependent ERK signalling pathway. J Cell Sci 2007; 120: 3544-3552.
31. Lark MW, Bayne EK, Flanagan J, et al: Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest 1997; 100: 93-106.
32. Yasumoto T, Bird JL, Sugimoto K, et al: The G1 domain of aggrecan released from porcine articular cartilage forms stable complexes with hyaluronan/link protein. Rheumatology (Oxford) 2003; 42: 336-342.
33. Chockalingam PS, Zeng W, Morris EA, et al: Release of hyaluronan and hyaladherins (aggrecan G1 domain and link proteins) from articular cartilage exposed to ADAMTS-4 (aggrecanase 1) or ADAMTS-5 (aggrecanase 2). Arthritis Rheum 2004; 50: 2839-2848.
34. Bau B, Gebhard PM, Haag J, et al: Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum 2002; 46: 2648-2657.
35. Pratta MA, Scherle PA, Yang G, et al: Induction of aggrecanase-1 (ADAM-TS4) by interleukin-1 occurs through activation of constitutively produced protein. Arthritis Rheum 2003; 48: 119-133.
36. Yamanishi Y, Boyle DL, Clark M, et al: Expression and regulation of aggrecanase in arthritis: the role of TGF-β. J Immunol 2002; 168: 1405-1412.
37. Koshy PJ, Lundy CJ, Rowan AD, et al: The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum 2002; 46: 961-967.
38. Bondeson J, Wainwright SD, Lauder S, et al: The role of synovial macrophages and macrophage-produced cytokins in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarhtritis. Arthritis Res Ther 2006; 8: R187.
39. Vankemmelbeke MN, Holen I, Wilson AG, et al: Expression and activity of ADAMTS-5 in synovium. Eur J Biochem 2001; 268: 1259-1268.
40. Stanton H, Rogerson FM, East CJ, et al: ADAMTS5 in the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 2005; 434: 648-652.
41. Zwerina J, Redlich K, Polzer K, et al: TNF-induced structural joint damage is mediated by IL-1. Proc Natl Acad Sci USA 2007; 104: 11742-11747.
42. Song RH, Tortorella MD, Malfait AM, et al: Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum 2007; 56: 575-585.
43. Little CB, Hughes CE, Curtis CL, et al: Cyclosporin A inhibition of aggrecanase-mediated proteoglycan catabolism in articular cartilage. Arthritis Rheum 2002; 46: 124-129.
44. Somerville RP, Longpre JM, Jungers KA, et al: characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to Caenorhabditis elegans GON-1. J Biol Chem 2003; 278: 9503-9513.
45. Collins-Racie LA, Flannery CR, Zeng W, et al: ADANTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. Matrix Biol 2004; 23: 219-230.
46. Patel KP, Sandy JD, Akeda K, et al: Aggrecanases and aggrecanase-generated fragments in the human intervertebral disc at early and advanced stages of disc degeneration. Spine 2007; 32 2596-2603.
47. Zeng W, Corcoran C, Collins-Racie LA, et al: Glycosaminoglycan-binding properties and aggrecanase activities of truncated ADAMTSs: comparative analysis with ADAMTS-5, -9, -16 and -18. Biochim Biophys Acta 2006; 1760: 517-524.
48. Malfait AM, Liu RQ, Ijiri K, et al: Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem 2002; 277: 22201-22208.
49. Glasson SS, Askew R, Sheppard B, et al: Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 2005; 434: 644-648.
50. Majumdar MK, Askew R, Schelling S, et al: Double-knockout of ADAMTS-4 and ADAMTS-5 in mice results in psysiologically normal animals and prevents the progression of osteoarthritis. Arthritis Rheum 2007; 56: 3670-3674.
51. Ilic MZ, East CJ, Rogerson FM, et al: Distinguishing aggrecan loss from aggrecan proteolysis in ADAMTS-4 and ADAMTS-5 single and double deficient mice. J Biol Chem 2007; 282: 37420-37428.
52. Matthews RI, Gary SC, Zerillo C, et al: Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member. J Biol Chem 2000; 275: 22695-22703.
53. Okada Y: Tumor cell-matrix interaction: pericellular matrix degradation and metastasis. Verh Dtsch Ges Pathol 2000; 84: 33-42.
54. 442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4 J Biol Chem 2001; 276: 13372-13378.
55. 406 to generate glial hyaluronate binding protein. Biochem J 2004; 377: 787-795.
56. Nakamura H, Fujii Y, Inoki I, et al: Brevican is degraded by matrix metalloproteinases and aggrecanase-1 (ADAMTS4) at different sites. J Biol Chem 2000; 275: 38885-38890.
57. Jaworski DM, Kelly GM, Hockfield S: Intracranial injury acutely induces the expression of the secreted isoform of the CNS specific hyaluronan-binding protein BEHAB/brevican. Exp Neurol 1999; 157: 327-337.
58. Zhang H, Kelly G, Zerillo C, et al: Expression of a cleaved brain-specific extracellular matrix protein mediates glioma cell invasion in vivo. J Neurosci 1998; 18: 2370-2376.
59. Melching LI, Fisher WD, Lee ER, et al: The cleavage of biglycan by aggrecanases. Osteoarthritis Cartilage 2006; 14: 1147-1154.
60. Rees SG, Flannery CR, Little CB, et al: Catabolism of aggrecan, decorin and biglycan in tendon. Biochem J 2000; 350: 181-188.
61. Malemud CJ: Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 2006; 11: 1696-1701.
62. Kashiwagi M, Enghild JJ, Gendron C, et al: Altered proteolytic activities of ADAMTS-4 expressed by C-terminal processing. J Biol Chem 2004; 279: 10109-10119.
63. Dickinson SC, Vankemmelbeke MN, Buttle DJ, et al: Cleavage of cartilage oligomeric matrix metalloproteinases and a disintegrin and metalloproteinase with thrombospondin motifs. Matrix Biol 2003; 22: 267-278.
64. Kashiwagi M, Tortorella M, Nagase H, et al: TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem 2001; 276: 12501-12504.
65. Wayne GJ, Deng SJ, Amour A, et al: TIMP-3 inhibition of ADAMTS-4 (Aggrecanase-1) is modulated by interactions between aggrecan and the C-terminal domain of ADAMTS-4. J Biol Chem 2007; 282: 20991-20998.
66. Nagase H, Brew K: Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochem Soc Symp 2003; 70: 201-212.
67. Hashimoto G, Aoki T, Nakamura H, et al: Inhibition of ADAMTS4 (aggrecanase-1) by tissue inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4). FEBS Lett 2001; 494: 192-195.
68. Gendron C, Kashiwagi M, Hughes C, et al: TIMP-3 inhibits aggrecanase-mediated glycosaminoglycan release from cartilage explants stimulated by catabolic factors. FEBS Lett 2003; 555: 431-436.
69. -/- mice. Arthritis Rheum 2007; 56: 905-909.
70. Mahmoodi M, Sahebjam S, Smookler D, et al: Lack of tissue inhibitor of metalloproteinases-3 results in an enhanced inflammatory response in antigen-induced arthritis. Am J Pathol 2005; 166: 1733-1740.
71. Curtis CL, Rees SG, Little CB, et al: Pathologic indicators of degradation and inflammation in human osteoarthritic cartilage are abrogated by exposure to n-3 fatty acids. Arthritis Rheum 2002; 46: 1544-1553.
72. Kramerova IA, Kawaguchi N, Fessler LI, et al: Papilin in development; a pericellular protein with a homology to the ADAMTS metalloproteinases. Development 2000; 127: 5475-5485.
73. Hashimoto G, Shimoda M, Okada Y: ADAMTS4 (aggrecanase-1) interaction with the C-terminal domain of fibronectin inhibits proteolysis of aggrecan. J Biol Chem 2004; 279: 32483-32491.
74. Bursavish MG, Gilbert AM, Lombardi S, et al: Synthesis and evaluation of aryl thioxothiazolidinone inhibitors of ADAMTS-5 (Aggrecanase-2). Bioorg Med Chem Lett 2007; 17: 1185-1188.
75. Bursavish MG, Gilbert AM, Lombardi S, et al: 5′-Phenyl-3′H-spiro[indoline-3,2′-[1,3,4] thiadiazol]-2-one inhibitors of ADAMTS-5 (aggrecanase-2). Bioorg Med Chem Lett 2007; 17: 5630-5633.
76. Fosang AJ, Rogerson FM, East CJ, et al: ADAMTS-5: the story so far. Eur Cell Mater 2008; 15: 11-26.
77. Durigova M, Soucy P, Fushimi K, et al: Characterization of an ADAMTS-4-mediated cleavage site in aggrecan in OSM-stimulated bovine cartilage. Osteoarthritis Cartilage 2008; 16: 1245-1252.
78. Fushimi K, Troeberg L, Nakamura H, et al: Functional differences of the catalytic and noncatalytic domains in human ADAMTS-4 and ADAMTS-5 in aggrecanolytic activity. J Biol Chem 2008; 283: 6706-6716.
79. Burrage PS, Brinckerhoff CE: Molecular targets in osteoarthritis: metalloproteinases and their inhibitors. Curr Drug Targets 2007; 8: 293-303.
80. Cherney RJ, Mo R, Meyer DT, et al: Potent and selective aggrecanase inhibitors containing cyclic P1 substituents. Bioorg Med Chem Lett 2003; 13: 1297-1300.
81. Thomas M, Sabatini M, Bensaude F, et al: A microplate assay for the screening of ADAMTS-4 inhibitors. Matrix Biol 2006; 25: 261-267.
82. Gilbert AM, Bursavich MG, Lombardi S, et al: 5-((1H-Pyrazol-4-yl)methylene)-2-thioxothiazolidin-4-one inhibitors of ADAMTS-5. Bioorg Med Chem Lett 2007; 17: 1189-1192.
83. Wittwer AJ, Hills RL, Keith RH, et al: Substrate-dependent inhibition kinetics of an active site-directed inhibitor of ADAMTS-4 (Aggrecanase 1). Biochemistry 2007; 46: 6393-6401.